Actively Recruiting

Age: 18Years +
All Genders
NCT05145244

Copenhagen Master Observational Trial

Led by Rigshospitalet, Denmark · Updated on 2025-07-24

2400

Participants Needed

1

Research Sites

334 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objectives of this prospective non-interventional study (NIS) are to assess and describe outcomes in relation to biomarkers, including whole-genome sequencing (WGS) in patients with non- small cell lung cancer (NSCLC) or breast cancer receiving treatment offered in the clinic (standard of care or included in clinical trials).

CONDITIONS

Official Title

Copenhagen Master Observational Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients 18 years of age or older with a diagnosis of NSCLC or breast cancer eligible for medical or radiation therapy with curative or palliative intent
  • Signed and dated informed consent indicating the patient has been informed about the study
  • Able to read and understand Danish
  • Willing and able to participate in data collection including whole-genome sequencing
Not Eligible

You will not qualify if you...

  • Patients with breast cancer starting adjuvant systemic therapy
  • Patients with a life expectancy fewer than 3 months at the time of NSCLC or breast cancer diagnosis as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Rigshospitalet

Copenhagen, Denmark, 2100

Actively Recruiting

Loading map...

Research Team

U

Ulrik Lassen, MD

CONTACT

A

Andreas Bjerrum, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here